Source comparison
Receptor Mechanism: Upstream Amplification vs Direct Agonism
CJC-1295 functions as a GHRH analog. It binds to G-protein-coupled receptors on pituitary somatotroph cells, triggering cyclic AMP (cAMP) accumulation and subsequent growth hormone secretion. The modified structure includes a Drug Affinity Complex (DAC). A che
This comparison does not assign a generated winner or score.
- CJC-1295 functions as a GHRH analog. It binds to G-protein-coupled receptors on pituitary somatotroph cells, triggering cyclic AMP (cAMP) accumulation and subsequent growth hormone secretion. The modified structure includes a Drug Affinity Complex (DAC). A chemical moiety that binds reversibly to serum albumin, extending the peptide's plasma half-life from minutes (native GHRH) to approximately 6–8 days. This prolonged circulation allows CJC-1295 to sustain elevated GH pulse amplitude without requiring continuous infusion, which is why research protocols dose it once or twice weekly rather than multiple times daily.
- IGF-1 LR3 operates downstream of the GH-IGF-1 axis entirely. Native IGF-1 circulates bound to IGF-binding proteins (IGFBPs), which regulate its bioavailability and half-life. The Long R3 modification reduces IGFBP affinity by approximately 90%, allowing the peptide to remain unbound and biologically active for significantly longer periods. Once free, IGF-1 LR3 binds directly to IGF-1 receptors. Tyrosine kinase receptors expressed on muscle, adipose, hepatic, and connective tissues. Initiating PI3K/Akt signaling cascades that drive protein synthesis, glucose uptake, and cell proliferation.
- The critical distinction: CJC-1295 requires a functional pituitary gland and hypothalamic-pituitary axis. IGF-1 LR3 does not. In research models examining GH deficiency, pituitary suppression, or age-related somatopause, IGF-1 LR3 remains effective because it bypasses the upstream regulatory mechanisms entirely. CJC-1295, by contrast, becomes progressively less effective in models with diminished pituitary responsiveness. The receptor is there, but the machinery to produce GH is impaired. This pharmacological reality shapes protocol design: CJC-1295 works best when the endogenous system is intact but suboptimal; IGF-1 LR3 works regardless of endogenous GH status.